GOVXWGeoVax Labs, Inc.
—Mkt Cap: —P/E: —368d ago
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The compa…
Industry Peers
Biotechnology$133.74BUSDP/E 30.8
$78.76BUSD
$77.45BUSDP/E 18.6
$60.46BUSDP/E 37.0
$57.09BUSDP/E 36.6
$44.04BUSDP/E 18.8
$43.24BUSD
$41.52BUSDP/E 65.7
$34.17BUSDP/E 44.6
$33.73BUSDP/E 31.4
$26.71BUSD
$25.70BUSD
$25.30BUSDP/E 15.9
$24.89BUSD
$21.74BUSDP/E 28.1
$20.62BUSDP/E 27.7
$15.47BUSDP/E 16.3
$15.13BUSDP/E 18.1
$14.46BUSDP/E 18.4
$13.02BUSD
Key Statistics
Company
Market Cap—
Enterprise Value—
Revenue (TTM)6.14M $
Gross Profit-18.95M $
Net Income (TTM)-21.46M $
Revenue/Share0.5680 USD
Last Price—
Fiscal Year End—
MR Quarter—
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B0.02
EPS (TTM)—
EPS (Forward)—
52W Range
—
52W High—
52W Low—
Profitability
Gross Margin0.00%
Oper. Margin-635.81%
EBITDA Margin0.00%
Profit Margin-862.34%
ROE-561.15%
ROA-338.46%
Growth
Revenue Growth183.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.47M $
CapEx (TTM)27.61K $
FCF Margin-297.06%
FCF Yield—
Net Debt-3.09M $
Net Debt/EBITDA0.12
Balance Sheet
Debt/Equity0.22
Current Ratio2.03
Quick Ratio1.43
Book Value/Sh0.1770 USD
Cash/Share0.1220 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.—
Float19.93M
Insiders—
Institutions—
Technical
SMA 50—
SMA 200—
Beta3.57
S&P 52W Chg16.25%
Avg Vol (30d)—
Avg Vol (10d)—
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—